Stay updated on Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.

Latest updates to the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated to include new collaborators, specifically GlaxoSmithKline, and a new EudraCT number related to HIV infections. Additionally, the revision number has changed from v2.14.4 to v2.15.0.SummaryDifference18%
- Check17 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check24 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check53 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check74 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.5%
- Check81 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
Stay in the know with updates to Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.